Community/Retail

The FDA has granted tentative approval to Merck's Lusduna Nexvue (insulin glargine injection) 100 units/mL. The drug is a follow-on biologic basal insulin for patients with type 2 diabetes and is administered through a pre-filled dosing device, according to a press release.

Officials with GSK announced that the US FDA has approved a new subcutaneous formulation of belimumab (Benlysta) for the treatment of adult patients with active, autoantibody‑positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Since the 2016 launch of AmerisourceBergen’s ABC Order, many within the organization have come to see the ordering platform as the first step in a larger effort to improve the experience of independent pharmacists.